{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-25-000028","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.450890+00:00","generated_at":"2026-05-24T06:23:21.800998+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AnaptysBio authorizes up to $75M stock repurchase plan","bullets":["Board authorized $75M buyback of outstanding common stock.","Company holds >$420M cash as of Dec 2024; expects $75M GSK milestone in 2025/2026.","Reiterates cash runway through year-end 2027, excluding potential GSK royalties.","Repurchases via open market under Rule 10b5-1; plan expires Dec 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-25-000028","json":"https://secwatch.observer/filing/0001370053-25-000028.json","markdown":"https://secwatch.observer/filing/0001370053-25-000028.md","text":"https://secwatch.observer/filing/0001370053-25-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000028/0001370053-25-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000028/anab-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:23:21.800998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}